Seamus Fernandez
Stock Analyst at Guggenheim
(3.43)
# 804
Out of 4,814 analysts
97
Total ratings
48.48%
Success rate
2.82%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $973 → $928 | $839.90 | +10.49% | 15 | Apr 14, 2025 | |
| MBX MBX Biosciences | Reiterates: Buy | $44 | $7.63 | +476.67% | 2 | Apr 10, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $13.01 | - | 3 | Apr 3, 2025 | |
| VERV Verve Therapeutics | Reiterates: Buy | n/a | $4.61 | - | 2 | Mar 25, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $30.50 | +424.59% | 4 | Mar 12, 2025 | |
| MTSR Metsera | Initiates: Buy | $56 | $17.55 | +219.09% | 1 | Feb 25, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | n/a | $13.26 | - | 2 | Feb 24, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | n/a | $33.05 | - | 7 | Feb 10, 2025 | |
| CDTX Cidara Therapeutics | Initiates: Buy | $33 | $19.44 | +69.75% | 1 | Nov 8, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $137 → $130 | $77.98 | +66.71% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $35.93 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $61.65 | +13.54% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.20 | +207.69% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.69 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.54 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $10.51 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $21.69 | +130.57% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $49.23 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $58.08 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $109.58 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.21 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.13 | +4,678.76% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $18.29 | +146.04% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $67.59 | -43.78% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $22.15 | +71.60% | 3 | Jan 31, 2018 |
Eli Lilly and Company
Apr 14, 2025
Maintains: Buy
Price Target: $973 → $928
Current: $839.90
Upside: +10.49%
MBX Biosciences
Apr 10, 2025
Reiterates: Buy
Price Target: $44
Current: $7.63
Upside: +476.67%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $13.01
Upside: -
Verve Therapeutics
Mar 25, 2025
Reiterates: Buy
Price Target: n/a
Current: $4.61
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $30.50
Upside: +424.59%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $17.55
Upside: +219.09%
Mineralys Therapeutics
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $13.26
Upside: -
Apogee Therapeutics
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $33.05
Upside: -
Cidara Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $33
Current: $19.44
Upside: +69.75%
Merck & Co.
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $77.98
Upside: +66.71%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $35.93
Upside: -
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $61.65
Upside: +13.54%
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $5.20
Upside: +207.69%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.69
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.54
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $10.51
Upside: -
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $21.69
Upside: +130.57%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $49.23
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $58.08
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $109.58
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.21
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.13
Upside: +4,678.76%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $18.29
Upside: +146.04%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $67.59
Upside: -43.78%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $22.15
Upside: +71.60%